Oxford Biodynamics PLC represents a commitment to revolutionizing personalized medicine through the application of biomarkers and genomic profiling. The company's core values prioritize scientific excellence, innovation, and collaboration to drive advancements in healthcare. Oxford Biodynamics PLC is dedicated to delivering accurate and reliable diagnostic solutions that enable early detection and monitoring of diseases, ultimately improving patient care and treatment outcomes. By leveraging its proprietary EpiSwitch™ technology, the company aims to transform the field of precision medicine, providing meaningful insights for drug discovery and development. Oxford Biodynamics PLC is driven by a strong corporate philosophy focused on scientific rigor, integrity, and a patient-centric approach.

Oxford Biodynamics PLC primarily operates and is present in various countries and regions around the world. The company has a global presence, with activities and partnerships in North America, Europe, and Asia. It collaborates with leading academic institutions, pharmaceutical companies, and research organizations in these regions. Oxford Biodynamics PLC's commitment to expanding its reach and establishing a strong international presence allows it to tap into a diverse range of markets and opportunities, strengthening its position in the global biotechnology industry.

Since its establishment, Oxford Biodynamics PLC has achieved several significant milestones that have propelled its growth and success. The company has made remarkable advancements in its proprietary EpiSwitch technology, which enables the detection and monitoring of diseases at an early stage. Oxford Biodynamics PLC has successfully developed collaborations with renowned institutions and organizations, paving the way for groundbreaking research and clinical applications. With its cutting-edge technology and strong scientific expertise, the company continues to make strides in the field of predictive biomarkers and personalized medicine. Oxford Biodynamics PLC's notable achievements further solidify its position as a leader in the healthcare industry.

Oxford Biodynamics PLC is a UK-based biotechnology company specializing in biomarker discovery and diagnostics. The company was founded in 2007 by University of Oxford professors, Sir Shankar Balasubramanian and Sir Edwin Southern. Oxford Biodynamics utilizes its proprietary EpiSwitch™ technology to analyze the epigenome and identify biomarkers that can be used for personalized medicine and drug development. The company's innovative approach has gained recognition within the industry, leading to numerous collaborations with pharmaceutical companies and academic institutions. With a strong focus on research and development, Oxford Biodynamics continues to make strides in the field of epigenetics and is poised to contribute significantly to advancements in healthcare.

Some of the main competitors of Oxford Biodynamics PLC in the market include companies like Illumina Inc., QIAGEN N.V., Bio-Rad Laboratories Inc., and Veracyte Inc. These companies also operate in the field of molecular biology and diagnostic testing, providing similar products and services. However, Oxford Biodynamics PLC distinguishes itself through its proprietary EpiSwitch™ technology, which enables highly accurate and non-invasive diagnostics with potential applications in various areas such as oncology and personalized medicine.

Oxford Biodynamics PLC is primarily active in the biotechnology industry.

Oxford Biodynamics PLC's business model is focused on the development and commercialization of biomarker discovery and diagnostic products. The company utilizes its proprietary technology platform, EpiSwitch™, to identify and analyze changes in the epigenetic signature of cells. By studying these epigenetic changes, Oxford Biodynamics can identify biomarkers that are linked to various diseases and conditions. These biomarkers can then be used for diagnostic purposes, drug development, and personalized healthcare. With a strong emphasis on epigenetics, Oxford Biodynamics aims to provide innovative solutions for improving patient outcomes and advancing precision medicine.

De K/W-verhouding kan momenteel niet worden berekend voor Oxford Biodynamics.

De KUV kan momenteel niet worden berekend voor Oxford Biodynamics.

De AlleAktien Kwaliteitsscore voor Oxford Biodynamics is 5/10.

De omzet kan momenteel niet worden berekend voor Oxford Biodynamics.

De winst kan momenteel niet berekend worden voor Oxford Biodynamics.

Oxford Biodynamics PLC (OBD) is a UK-based biotechnology company focused on the development of non-invasive diagnostic and prognostic tools based on epigenetics. The company utilizes the latest technologies and methods to gain a comprehensive understanding of epigenetic processes and convert them into medically actionable data. OBD has two main business segments: diagnostics and pharma. In the diagnostics field, the company focuses on developing biomarkers based on epigenetic changes associated with specific diseases. These biomarkers serve as non-invasive prognostic and diagnostic tools, enabling physicians and researchers to detect and treat diseases early. Diseases for which OBD offers diagnostic solutions include cancer, Alzheimer's, and Parkinson's. In the pharma sector, OBD collaborates with pharmaceutical companies to develop epigenetic therapies that have the potential to cure diseases or alleviate their symptoms. These therapies are based on understanding how epigenetic processes influence gene expression and how they can be manipulated to address specific disease causes. Diseases for which OBD offers pharma solutions include cancer, Alzheimer's, inflammation, and autoimmune diseases. One of the technologies OBD uses to develop its products and services is EpiSwitch, a proprietary platform that allows monitoring changes in the epigenetic signature of cells. By analyzing epigenetics, OBD can create a comprehensive profile of an individual's DNA, gaining a better understanding of the underlying epigenetic processes associated with disease onset and progression. OBD also offers customized services and solutions to meet the needs of its clients. These services include epigenetic profiling, diagnostic and prognostic tools, and consulting services. With these services, OBD can develop customized solutions that meet the needs of pharmaceutical companies, research institutions, and government agencies. Overall, OBD's business model is based on leveraging the latest technologies and methods to gain a better understanding of epigenetic processes associated with diseases. By developing non-invasive diagnostic and prognostic tools, as well as epigenetic therapies, OBD offers solutions that have the potential to save and improve many lives.

Oxford Biodynamics keert een dividend van 0 GBP uit, verdeeld over betalingen per jaar.

De dividend kan momenteel niet worden berekend voor Oxford Biodynamics of het bedrijf keert geen dividend uit.

De ISIN van Oxford Biodynamics is GB00BD5H8572.

Het WKN van Oxford Biodynamics is A2DH0R.

De ticker van Oxford Biodynamics is OBD.L.

Binnen de laatste 12 maanden betaalde Oxford Biodynamics een dividend van . Dit komt overeen met een dividendrendement van ongeveer . Voor de komende 12 maanden zal Oxford Biodynamics naar verwachting een dividend van 0 GBP betalen.

De dividendrendement van Oxford Biodynamics is momenteel .

Oxford Biodynamics betaalt elk kwartaal een dividend uit. Dit wordt uitgekeerd in de maanden .

Oxford Biodynamics betaalde de afgelopen 0 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 0 GBP verwacht. Dit komt overeen met een dividendrendement van 0 %.

Oxford Biodynamics wordt toegewezen aan de sector 'Gezondheid'.

Om het laatste dividend van Oxford Biodynamics van 5-11-2024 ter hoogte van 0 GBP te ontvangen, moest je het aandeel voor de ex-datum op 5-11-2024 in je portefeuille hebben.

De laatste dividenduitkering vond plaats op 5-11-2024.

In het jaar 2023 heeft Oxford Biodynamics 0 GBP aan dividenden uitgekeerd.

De dividenden van Oxford Biodynamics worden in GBP uitgekeerd.